Abstract
Cardiogenic shock (CS) is a complex and dreadful condition for which effective treatments remain unclear. The concerningly high mortality rate of CS emphasizes a need for developing effective therapies to reduce its mortality and reverse its detrimental course. This article aims to provide an updated and evidence-based review of the pathophysiology of CS and the related pharmacotherapeutics with a special focus on vasoactive and inotropic agents.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference29 articles.
1. Shock – classification and pathophysiological principles of therapeutics;Kislitsina;Curr Cardiol Rev,2019
2. Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock;Schrage;ESC Heart Fail,2021
3. Acute cardiovascular care association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: a document of the acute cardiovascular care association of the European Society of Cardiology;Zeymer;Eur Heart J,2020
4. Circulatory shock;Vincent;N Engl J Med,2013
5. What’s new in cardiogenic shock?;de Chambrun;Intensive Care Med,2020